Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation

Radiotherapy and Oncology

Volumn 109, Issue 2, 2013, Pages 241-245

  Ohashi, Toshio ^a,b   Yorozu, Atsunori ^c   Saito, Shiro ^c   Momma, Tetsuo ^b   Toya, Kazuhito ^c   Nishiyama, Toru ^c   Yamashita, Shoji ^b   Shiraishi, Yutaka ^a   Shigematsu, Naoyuki ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAITAMA NATIONAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Brachytherapy; Prostate cancer; Seed implant

Indexed keywords

HORMONE; IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; CANCER HORMONE THERAPY; CAUSE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RECTUM HEMORRHAGE; TREATMENT OUTCOME; URINARY URGENCY; URINE RETENTION;

BRACHYTHERAPY; PROSTATE CANCER; SEED IMPLANT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 84889578121     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.09.022     Document Type: Article

References (29)

1. L. Potters, E.A. Klein, and M.W. Kattan Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation Radiother Oncol 71 2004 29 33
2. P.A. Kupelian, L. Potters, and D. Khuntia Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
3. B.R. Pieters, D.Z. de Back, C.C. Koning, and A.H. Zwinderman Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review Radiother Oncol 93 2009 168 173
4. G. Goldner, R. Potter, and J.J. Battermann Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients Radiother Oncol 103 2012 223 227
5. M.J. Zelefsky, Y. Yamada, and X. Pei Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer Urology 77 2011 986 990
6. N. Bittner, G.S. Merrick, and R.W. Galbreath Primary causes of death after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 72 2008 433 440
7. J. Crook, J. Borg, and A. Evans 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1100 patients Int J Radiat Oncol Biol Phys 80 2011 1323 1329
8. J.E. Sylvester, P.D. Grimm, J. Wong, R.W. Galbreath, G. Merrick, and J.C. Blasko Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience Int J Radiat Oncol Biol Phys 81 2011 376 381
9. J. Kao, N.N. Stone, A. Lavaf, V. Dumane, J.A. Cesaretti, and R.G. Stock (125)I monotherapy using D90 implant doses of 180 Gy or greater Int J Radiat Oncol Biol Phys 70 2008 96 101
10. F. Guedea, F. Aguilo, and A. Polo Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer Radiother Oncol 80 2006 57 61
11. S.H. Aaltomaa, V.V. Kataja, T. Lahtinen, J.E. Palmgren, and T. Forsell Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy - morbidity and outcome results Radiother Oncol 91 2009 213 216
12. C. Herbert, W.J. Morris, and M. Keyes Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study Radiother Oncol 103 2012 228 232
13. T. Ohashi, A. Yorozu, K. Toya, S. Saito, and T. Momma Acute urinary morbidity following I-125 prostate brachytherapy Int J Clin Oncol 10 2005 262 268
14. T. Ohashi, A. Yorozu, and K. Toya Comparison of intraoperative ultrasound with postimplant computed tomography - dosimetric values at Day 1 and Day 30 after prostate brachytherapy Brachytherapy 6 2007 246 253
15. Onsensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel Int J Radiat Oncol Biol Phys 37 1997 1035 1041
16. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
17. M.J. Zelefsky, D.A. Kuban, and L.B. Levy Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327 333
18. R.G. Stock, N.N. Stone, J.A. Cesaretti, and B.S. Rosenstein Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results Int J Radiat Oncol Biol Phys 64 2006 527 533
19. M.J. Zelefsky, J.F. Chou, and X. Pei Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: the Memorial Sloan-Kettering Cancer Center experience Brachytherapy 11 2012 245 249
20. N.N. Stone, L. Potters, and B.J. Davis Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes Int J Radiat Oncol Biol Phys 69 2007 1472 1477
21. N.P. Munro, B. Al-Qaisieh, and P. Bownes Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years Radiother Oncol 96 2010 34 37
22. D. Ash, B. Al-Qaisieh, D. Bottomley, B. Carey, and J. Joseph The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer Radiother Oncol 79 2006 185 189
23. A. Gomez-Iturriaga Pina, J. Crook, J. Borg, and C. Ma Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) >/=180 Gy Int J Radiat Oncol Biol Phys 78 2010 422 427
24. B.J. Davis, E.M. Horwitz, and W.R. Lee American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy Brachytherapy 11 2012 6 19
25. A.V. Taira, G.S. Merrick, and W.M. Butler Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 79 2011 1336 1342
26. D. Ash, B. Al-Qaisieh, D. Bottomley, B. Carey, and J. Joseph The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer Radiother Oncol 75 2005 303 306
27. K.O. Castle, K.E. Hoffman, and L.B. Levy Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 85 2013 693 699
28. K. Yamoah, N. Stone, and R. Stock Impact of race on biochemical disease recurrence after prostate brachytherapy Cancer 117 2011 5589 5600
29. L.N. Lee, C. Barnswell, T. Torre, P. Fearn, M. Kattan, and L. Potters Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses Int J Radiat Oncol Biol Phys 53 2002 282 289